Cargando…

Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study

Cisplatin-based chemotherapy is the primary treatment for metastatic bladder urothelial carcinoma (UC). Most patients inevitably encounter drug resistance and resultant disease relapse. Reduced apoptosis plays a critical role in chemoresistance. Trifluoperazine (TFP), an antipsychotic agent, has dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuo, Kuan-Lin, Liu, Shing-Hwa, Lin, Wei-Chou, Hsu, Fu-Shun, Chow, Po-Ming, Chang, Yu-Wei, Yang, Shao-Ping, Shi, Chung-Sheng, Hsu, Chen-Hsun, Liao, Shih-Ming, Chang, Hong-Chiang, Huang, Kuo-How
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651283/ https://www.ncbi.nlm.nih.gov/pubmed/31262032 http://dx.doi.org/10.3390/ijms20133218

Ejemplares similares

MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma
por: Ho, I-Lin, et al.
Publicado: (2015)

The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma
por: Chow, Po-Ming, et al.
Publicado: (2022)

PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study
por: Hsu, Fu-Shun, et al.
Publicado: (2021)

Sertindole, an Antipsychotic Drug, Curbs the STAT3/BCL-xL Axis to Elicit Human Bladder Cancer Cell Apoptosis In Vitro
por: Hsu, Chao-Yu, et al.
Publicado: (2023)

The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study
por: Kuo, Kuan-Lin, et al.
Publicado: (2019)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Activity of Trifluoperazine against Replicating, Non-Replicating and Drug Resistant M. tuberculosis
por: Advani, Meeta J., et al.
Publicado: (2012)

Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis
por: Xia, Yong, et al.
Publicado: (2019)

β-catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl
por: ZHANG, JIN, et al.
Publicado: (2016)

The Food and Drug Administration-approved antipsychotic drug trifluoperazine, a calmodulin antagonist, inhibits viral replication through PERK-eIF2α axis
por: Mao, Yizhi, et al.
Publicado: (2022)

Celecoxib-Induced Cytotoxic Effect Is Potentiated by Inhibition of Autophagy in Human Urothelial Carcinoma Cells
por: Huang, Kuo-How, et al.
Publicado: (2013)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
por: Haselager, Marco, et al.
Publicado: (2021)

Trifluoperazine and Its Analog Suppressed the Tumorigenicity of Non-Small Cell Lung Cancer Cell; Applicability of Antipsychotic Drugs to Lung Cancer Treatment
por: Jeong, Joo Yeon, et al.
Publicado: (2022)

Trifluoperazine prevents FOXO1 nuclear excretion and reverses doxorubicin-resistance in the SHG44/DOX drug-resistant glioma cell line
por: Chen, Xiaozhong, et al.
Publicado: (2018)

Trifluoperazine-Induced Angioedema
por: Osman, Mugtaba, et al.
Publicado: (2014)

FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression
por: Wang, Wei, et al.
Publicado: (2016)

Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression
por: Song, Yanfang, et al.
Publicado: (2021)

An increase in glucosylceramide synthase induces Bcl-xL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells
por: Chiu, Wei-Hsin, et al.
Publicado: (2015)

Pseudo-tetanus following trifluoperazine.
por: Shorten, G. D., et al.
Publicado: (1990)

Trifluoperazine-Induced Cholestatic Jaundice
por: Sharifi, Vandad, et al.
Publicado: (2010)

Hypokalemia with Trifluoperazine at Therapeutic Dose
por: Rehman, Sajjadur, et al.
Publicado: (2017)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
por: Lopez, Andrea, et al.
Publicado: (2022)

Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study
por: Shi, Chung-Sheng, et al.
Publicado: (2019)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
por: Li, Ji-Yu, et al.
Publicado: (2012)

Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma
por: Luanpitpong, Sudjit, et al.
Publicado: (2022)

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Bcl-xL mutant promotes cartilage differentiation of BMSCs by upregulating TGF-β/BMP expression levels
por: Xiao, Kai, et al.
Publicado: (2021)

From GWAS to drug screening: repurposing antipsychotics for glioblastoma
por: Lin, Wei-Zhi, et al.
Publicado: (2022)

Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation
por: Keitel, Ulrike, et al.
Publicado: (2014)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)

Inhibition of dengue virus infection by trifluoperazine
por: Piccini, Luana E., et al.
Publicado: (2022)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway
por: Hsu, Fu-Shun, et al.
Publicado: (2019)

Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL
por: Hari, Yoko, et al.
Publicado: (2015)

Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
por: Liu, Qian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jmaevt3f3abh1q1dj4k2r30vh4